The potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker

Ka Won Kang, Jik Han Jung, Woojune Hur, Jaena Park, Hyunku Shin, Byeonghyeon Choi, Hyesun Jeong, Dae Sik Kim, Eun Sang Yu, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, Chul Won Choi, Hyun Koo Kim, Sunghoi Hong, Ji Ho Park, Yeonho Choi, Yong Park, Byung Soo Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)


Background/Aim: Exosomes, derived from chronic myelogenous leukaemia (CML) cells, can be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This study aimed to identify these possibilities. Materials and Methods: Human CML cell line-derived exosomes and CML-patients-derived exosomes were isolated with a size-exclusion chromatography column and ExoQuick™ exosome precipitation solution, respectively. Isolated exosomes were analysed by nested PCR to detect the BCR-ABL transcript. Results: Exosomes derived from the two human CML cell lines yielded a 250-bp band. RNA sequence analysis revealed 99% sequence homology with the partial mRNA for the human BCR-ABL chimeric protein. This ~250-bp band was also observed in the exosomes derived from patients with CML. However, only patients at the blast and accelerated phases showed the exosomal BCR-ABL transcript. Conclusion: CML-derived exosomes could act as novel targets for the detection of the BCR-ABL transcript.

Original languageEnglish
Pages (from-to)3935-3942
Number of pages8
JournalAnticancer Research
Issue number7
Publication statusPublished - 2018 Jul 1



  • Biomarker
  • Chronic myelogenous leukaemia
  • Exosome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this